Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2022 Apr 24

PMID 35461424

Authors

Regina Matar

Varadan Sevilimedu

Mary L Gemignani

Monica Morrow

Affiliations

Soon will be listed here.

Abstract

Background: National Comprehensive Center Network guidelines recommend radiotherapy (RT) omission in women age ≥ 70 years with estrogen receptor-positive (ER+), cN0, T1 tumors post-lumpectomy if they receive endocrine therapy (ET). However, little is known about the impact of poor adherence on locoregional recurrence (LRR) in elderly women forgoing RT.

Methods: Women age ≥ 70 years with pT1-2 ER+ breast cancer undergoing lumpectomy without RT from 2004 to 2019 were identified from a prospectively maintained database. ET adherence, calculated as treatment duration over follow-up time up to 5 years, was determined by chart review. We compared clinicopathologic characteristics and rates of LRR between women with high adherence (≥ 80%), low adherence (< 80%), and no ET.

Results: Of 968 women (27 bilateral cancers), adherence was high in 676 (70%) and low in 162 (17%); 130 (13%) took no ET. Younger age and use of aromatase inhibitor were associated with high adherence. On multivariable analysis, tumor size (hazard ratio [HR] 1.67, 95% confidence interval [CI] 1.03-2.68, p = 0.04) and high adherence (HR 0.13, 95% CI 0.07-0.26, p < 0.001) were significantly associated with LRR. At 53 months median follow-up, the 5-year rate of LRR was 3.1% (95% CI 2.4-3.9%) with high adherence, 14.7% (95% CI 11.7-17.7%) with low adherence, and 17.9% (95% CI 13.9-21.8%) with no ET (p < 0.01).

Conclusions: Although adherence to ET was high overall, in the 30% of women with low adherence or no ET, LRR rates were significantly increased. Counseling regarding the distinct toxicities of ET and RT can help patients choose the therapy to which they will likely adhere to.

Citing Articles

Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer.

Wang H, Yu M, Chen M, Li H, Liu S Breast Cancer (Dove Med Press). 2024; 16:785-793.

PMID: 39588273 PMC: 11586453. DOI: 10.2147/BCTT.S495183.

Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2- breast cancer: a propensity score-matched retrospective cohort study using the SEER database.

Ma X, Wu S, Zhang X, Chen N, Yang C, Yang C BMJ Open. 2024; 14(3):e078782.

PMID: 38490656 PMC: 10946384. DOI: 10.1136/bmjopen-2023-078782.

Whole Breast Irradiation in Comparison to Endocrine Therapy in Early Stage Breast Cancer-A Direct and Network Meta-Analysis of Published Randomized Trials.

Haussmann J, Budach W, Corradini S, Krug D, Bolke E, Tamaskovics B Cancers (Basel). 2023; 15(17).

PMID: 37686620 PMC: 10487067. DOI: 10.3390/cancers15174343.

Recent Advances in Optimizing Radiation Therapy Decisions in Early Invasive Breast Cancer.

Riaz N, Jeen T, Whelan T, Nielsen T Cancers (Basel). 2023; 15(4).

PMID: 36831598 PMC: 9954587. DOI: 10.3390/cancers15041260.

References

Cahir C, Barron T, Sharp L, Bennett K . Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?. Cancer Causes Control. 2017; 28(3):215-225. DOI: 10.1007/s10552-017-0851-9. View

Partridge A, Wang P, Winer E, Avorn J . Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003; 21(4):602-6. DOI: 10.1200/JCO.2003.07.071. View

Blanchette P, Lam M, Richard L, Allen B, Shariff S, Vandenberg T . Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Breast Cancer Res Treat. 2019; 179(1):217-227. DOI: 10.1007/s10549-019-05430-6. View

Tringale K, Berger E, Sevilimedu V, Wen H, Gillespie E, Mueller B . Breast conservation among older patients with early-stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy. Cancer. 2021; 127(11):1749-1757. PMC: 8113065. DOI: 10.1002/cncr.33422. View

Lambert L, Balneaves L, Howard A, Gotay C . Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat. 2017; 167(3):615-633. DOI: 10.1007/s10549-017-4561-5. View

Kunkler I, Williams L, Jack W, Cameron D, Dixon J . Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015; 16(3):266-73. DOI: 10.1016/S1470-2045(14)71221-5. View

Hershman D, Shao T, Kushi L, Buono D, Tsai W, Fehrenbacher L . Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2010; 126(2):529-37. PMC: 3462663. DOI: 10.1007/s10549-010-1132-4. View

Fyles A, McCready D, Manchul L, Trudeau M, Merante P, Pintilie M . Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004; 351(10):963-70. DOI: 10.1056/NEJMoa040595. View

Diab S, Elledge R, Clark G . Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000; 92(7):550-6. DOI: 10.1093/jnci/92.7.550. View

10.

Font R, Espinas J, Barnadas A, Izquierdo A, Galceran J, Saladie F . Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. Breast Cancer Res Treat. 2019; 175(3):733-740. DOI: 10.1007/s10549-019-05201-3. View

11.

Carlson R, Moench S, Hurria A, Balducci L, Burstein H, Goldstein L . NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25. View

12.

Thurlimann B, Keshaviah A, Coates A, Mouridsen H, Mauriac L, Forbes J . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353(26):2747-57. DOI: 10.1056/NEJMoa052258. View

13.

Rosenberg P, Barker K, Anderson W . Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States. J Natl Cancer Inst. 2015; 107(9). PMC: 4836802. DOI: 10.1093/jnci/djv159. View

14.

. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351(9114):1451-67. View

15.

Colzani E, Johansson A, Liljegren A, Foukakis T, Clements M, Adolfsson J . Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer. 2014; 110(5):1378-84. PMC: 3950882. DOI: 10.1038/bjc.2014.5. View

16.

Doggrell S . Adherence to oral endocrine treatments in women with breast cancer: can it be improved?. Breast Cancer Res Treat. 2011; 129(2):299-308. DOI: 10.1007/s10549-011-1578-z. View

17.

van Herk-Sukel M, van de Poll-Franse L, Voogd A, Nieuwenhuijzen G, Coebergh J, Herings R . Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010; 122(3):843-51. DOI: 10.1007/s10549-009-0724-3. View

18.

Hershman D, Kushi L, Shao T, Buono D, Kershenbaum A, Tsai W . Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010; 28(27):4120-8. PMC: 2953970. DOI: 10.1200/JCO.2009.25.9655. View

19.

Owusu C, Buist D, Field T, Lash T, Thwin S, Geiger A . Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2007; 26(4):549-55. DOI: 10.1200/JCO.2006.10.1022. View

20.

Hughes K, Schnaper L, R Bellon J, Cirrincione C, Berry D, McCormick B . Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013; 31(19):2382-7. PMC: 3691356. DOI: 10.1200/JCO.2012.45.2615. View